Premium
3‐({2, 4‐dimethyl‐5‐[ 123 I]IODO}benzylidene) anabaseine: A potent spect agent for imaging lung cancer
Author(s) -
Zhang J. H.,
Akula M. R.,
Kabalka G. W.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401126
Subject(s) - lung cancer , cancer , medicine , lung , incidence (geometry) , oncology , prostate , prostate cancer , physics , optics
Lung cancer is the leading cause of cancer deaths among American men and women with a mortality rate of >90% within five years of diagnosis (1). Unlike cancers at other organ sites which have declined during the past decade, the incidence of lung cancer continues to rise, particularly in women and black Americans (2). This trend will further escalate within the next three decades due to a sharp increase in teenage smoking. Cancers at other organ sites such as breast and prostate, are more than twice as common but their cure rates are 80 and 70%, respectively, because of early detection and available therapeutic regimen based on identified mechanisms of the diseases. The family of neuroendocrine lung tumors [carcinoids, atypical carcinoids, and small cell lung carcinoma (SCLC)] accounts for 35% of all human lung cancer cases (2). The early detection of these tumors is of great significance as it helps physicians plan for effective treatment.